Prof. Artur Jurczyszyn

 

     

 

Artur Jurczyszyn, MD, PhD
Professor of Medicine
Head of the Plasma Cell Dyscrasias Center
Jagiellonian University Medical College, Kraków, Poland

Artur Jurczyszyn is Professor of Medicine at the Department of Hematology, Jagiellonian University Medical College, and Head of the Plasma Cell Dyscrasias Center in Kraków, Poland. A specialist in hematology and internal medicine, he combines three decades of clinical experience with research dedicated to improving outcomes for patients with multiple myeloma and related disorders.

His research focuses particularly on rare and aggressive presentations of plasma cell malignancies, including plasma cell leukemia, extramedullary disease, central nervous system involvement, and myeloma in young adults. Through international, multicenter collaborations, he has contributed to studies advancing the understanding of these challenging conditions and their prognostic factors. He has authored or co-authored more than 250 scientific publications and served as scientific editor of monographs on clinical hematology.

Professor Jurczyszyn graduated from the Jagiellonian University in 1996, received his PhD in 2003, completed his habilitation in 2016, and was awarded the title of Professor of Medical and Health Sciences in 2021. In 2025, he was elected a Corresponding Member of the Polish Academy of Arts and Sciences.

He is a member of the International Myeloma Working Group, the International Myeloma Society, the European Hematology Association, and the American Society of Hematology. His distinctions include the Tadeusz Browicz Award of the Polish Academy of Arts and Sciences and national ministerial awards for scientific achievement.

Beyond his academic and clinical work, he is co-founder and President of the Myeloma Treatment Center Foundation, established in 2008. Through its educational, publishing, rehabilitation, and patient-support initiatives, he promotes comprehensive care that addresses both the medical and everyday challenges of living with myeloma. His work brings together scientific rigor, international collaboration, and a sustained commitment to patients and their families.